Summit Therapeutics Inc. (SMMT) stock
Close on Nov 13, 2026Market cap $11.29BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $11.29B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 19.99
- Dividend yield
- –
- Free cash flow yield
- -4.67%
Fundamentals
- Net income
- -$832.68M
- EPS, diluted
- -$1.07
- Free cash flow
- -$526.88M
- Book value per share
- $0.71
- Diluted shares
- 798M
Trading
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Previous close
- $15.07
- Open
- $15.20
- Day's range
- $14.06 – $15.20
- Volume
- 5,555,312
- Average volume (20 days)
- 4,844,579
- Index membership
- Russell 1000 (since Jun 2025), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.38
- 52-week range
- $12.07 – $29.23
- RSI (14 days)
- 42.2
- Volatility (1 year)
- 75.8%
- Relative volume
- 1.01×
- WACC
- 7.6%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SMMT | S&P 500 | Difference | SMMT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.8% | -3.0% | −5.8 pts | ||
| 3 months | +1.1% | -2.8% | +3.9 pts | ||
| Year to date | -19.1% | +11.5% | −30.6 pts | ||
| 1 year | -22.5% | +13.5% | −36.0 pts | ||
| 3 years | +669.0% | +77.7% | +591.3 pts | +97.4% | +21.1% |
| 5 years | +162.0% | +72.6% | +89.4 pts | +21.2% | +11.5% |
| 10 years | +28.5% | +308.2% | −279.6 pts | +2.5% | +15.1% |
Nine years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Summit Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- News
About Summit Therapeutics
Pharmaceutical Preparations
Summit Therapeutics Inc. is a biopharmaceutical company engaged in discovering, developing, and commercializing medicinal therapies in the oncology sector. Its principal lead investigational candidate is ivonescimab, a bispecific antibody designed to combine anti-angiogenesis and immunotherapy targeting VEGF and PD-1 pathways. The company focuses on developing treatments for patients with solid tumor malignancies, primarily evaluating clinical indications in non-small cell lung cancer and colorectal cancer.
Company profile, executives and historySummit Therapeutics stock: common questions
What is Summit Therapeutics's stock price?
SMMT closed at $14.15 on Nov 13, 2026, down 6.14% on the day. Over the past 52 weeks it traded between $12.07 and $29.23.
What is Summit Therapeutics's market cap?
Summit Therapeutics was worth $11.29B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SMMT's P/E ratio?
Summit Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.07), so it has no meaningful P/E ratio.
Does Summit Therapeutics pay a dividend?
No. Summit Therapeutics has not paid a cash dividend over the last twelve months.
When does Summit Therapeutics report earnings next?
Summit Therapeutics is expected to report Q4 FY2026 results on Feb 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SMMT stock performed over the past year?
Including dividends, SMMT returned -22.5% over the past year, against +13.5% for the S&P 500.
Who are Summit Therapeutics's competitors?
Companies most similar to Summit Therapeutics by business, industry and size include CBIO, AVBP, BCAX, IMNM, PYXS.
See a number that looks wrong?